Please login to the form below

Not currently logged in
Email:
Password:

BMS appoints Elliott Sigal to Board

Bristol-Myers Squibb has appointed Dr Elliott Sigal to its Board of Directors and to the Board's science and technology committee

Bristol-Myers Squibb (BMS) has appointed Dr Elliott Sigal to its Board of Directors and to the Board's science and technology committee.

Sigal joined BMS in 1997 as vice president of applied genomics. He has since served in critical leadership roles within R&D, including drug discovery and development. During Sigal's time as chief scientific officer, BMS achieved eight new drug approvals and filled the drug pipeline with numerous mid- and late-stage assets, five of which could be approved by 2012. 

"We are very excited to have Elliott join our Board," said James M Cornelius, chairman, Bristol-Myers Squibb. "Under his leadership, our R&D organisation has become one of the most productive in the industry. Today's appointment recognises his great contribution to the company." 
Sigal has held the role of executive vice president, chief scientific officer and president, BMS research and development since 2004. He reports to Lamberto Andreotti, CEO, BMS.

2nd March 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics